調査・レポート
2026年8月30日•1分で読めます
Immunomic Therapeutics Completes First Patient Dosing in Phase 1 Trial of ITI-9001 for Japanese Cedar Pollen Allergy
Immunomic Therapeutics reported first patient dosing in a Phase 1 trial of ITI-9001, a Japanese cedar pollen allergy vaccine, with no safety issues observed.
調査・レポート
2026年8月24日•1分で読めます
PMDA Workshop on New Approach Methodologies (NAMs) Held after ICCR‑20
The Pharmaceuticals and Medical Devices Agency (PMDA) held a workshop on New Approach Methodologies (NAMs) following the ICCR‑20 symposium.
1
調査・レポート
2026年8月23日•1分で読めます
PMDA Concludes MoU with London School of Hygiene & Tropical Medicine
The Pharmaceuticals and Medical Devices Agency (PMDA) has signed a Memorandum of Understanding with the London School of Hygiene & Tropical Medicine to promote joint work in pharmaceutical research and regulatory science.